Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Scanlon, P H; Loftus, J; Starita, C; Stratton, I M (2014)
Publisher: BlackWell Publishing Ltd
Journal: Diabetic Medicine
Languages: English
Types: Article
Subjects: RC0254, RE, Research Articles

Classified by OpenAIRE into

mesheuropmc: genetic structures, eye diseases
Aims\ud \ud \ud To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema.\ud \ud \ud Methods\ud \ud \ud Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related QoL was determined using the European Quality of Life EQ–5D–3L and the Visual Functioning Questionnaire–25 (NEI–VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control.\ud \ud \ud Results\ud \ud \ud For all vision-related QoL domains from NEI–VFQ25 and EQ–5D–3L except ocular pain, both visual acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The NEI–VFQ25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye.\ud \ud \ud Conclusions\ud \ud \ud We recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 International Diabetes Federation. IDF Diabetes Atlas, 2013. Available at http://www.idf.org/diabetesatlas Last accessed 16 April 2014.
    • 2 Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Org 2004; 82: 844-851.
    • 3 Keenan TD, Johnston RL, Donachie PHJ, Sparrow JM, Stratton IM, Scanlon PH. United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye (Lond) 2013; 27: 1397-1404.
    • 4 Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M. Diabetic retinopathy and health-related quality of life. Graefes Arch Clin Exp Ophthalmol 2009; 247: 267-272.
    • 5 Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 2008; 92: 89-92.
    • 6 Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011; 118: 1107-1118.
    • 7 Pleil AM, Cappelleri JC, Chisholm JA, Getter CA, Lustig S, Reichel MB. An interpretation of quality of life based on binocular visual acuity in German patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004; 45. Available at http://abstracts. iovs.org/cgi/content/abstract/45/5/1369 Last accessed 16 April 2014.
    • 8 EuroQol Group. EQ-5D User Guide, 2013. Available at http:// www.euroqol.org/about-eq-5d/publications/user-guide.html Last accessed 16 April 2014.
    • 9 MVH_Group. The Measurement and Valuation of Health: Final Report on the Modelling of Valuation Tariffs. Centre for Health Economics, University of York, 1995.
    • 10 Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119: 1050-1058.
    • 11 Clinical Trials.gov. A Multi-Center Trial to Evaluate the Safety and Efficacy of Pegaptanib Sodium (Macugen) Injected into the Eye Every 6 Weeks for up to 2 Years for Macular Swelling Associated with Diabetes, with an Open-Label Macugen Year Extension. Available at clinicaltrials.gov/ct2/show/results/NCT00605280 Last accessed 16 April 2014.
    • 12 Brown MM, Brown GC, Sharma S, Hollands H, Landy J. Quality of life and systemic comorbidities in patients with ophthalmic disease. Br J Ophthalmol 2002; 86: 8-11.
    • 13 Scanlon PH, Martin ML, Bailey C, Johnson E, Hykin P, Keightley S. Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy. Diabetes Med 2006; 23: 60-66.
    • 14 Wu S, Nemesure B, Hennis A, Leske M. Visual acuity impairment and vision-related quality of life: the Barbados Eye Studies. Br J Visual Impairment 2009; 27: 9-24.
    • 15 Fenwick EK, Xie J, Ratcliffe J, Pesudovs K, Finger RP, Wong TY et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci 2012; 53: 677-684.
    • 16 Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health 2012; 15: 118-127.
    • 17 Kay S, Ferreira A. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores. Ophthalmic Epidemiol 2014; 21: 66-78.
    • 18 Poku E, Brazier J, Carlton J, Ferreira A. Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review. BMC Ophthalmol 2013; 13: 74.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article